Galectin Therapeutics Inc. (GALT)
NASDAQ: GALT · Real-Time Price · USD
1.490
+0.020 (1.36%)
Feb 21, 2025, 4:00 PM EST - Market closed
Galectin Therapeutics Employees
Galectin Therapeutics had 14 employees as of December 31, 2023. The number of employees increased by 2 or 16.67% compared to the previous year.
Employees
14
Change (1Y)
2
Growth (1Y)
16.67%
Revenue / Employee
n/a
Profits / Employee
-$3,230,714
Market Cap
93.52M
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 440,000 |
Johnson & Johnson | 131,900 |
Thermo Fisher Scientific | 122,000 |
Abbott Laboratories | 114,000 |
AstraZeneca | 92,900 |
Novo Nordisk | 77,349 |
Novartis AG | 75,883 |
Merck & Co. | 72,000 |
GALT News
- 6 weeks ago - Galectin Therapeutics to Present at the 2025 MASH-TAG Conference - GlobeNewsWire
- 2 months ago - Why Is Small Cap Galectin Therapeutics Stock Trading Lower On Friday? - Benzinga
- 2 months ago - Galectin Therapeutics Announces Top-Line Results of NAVIGATE Clinical Trial Evaluating Belapectin in Patients with Cirrhotic Portal Hypertension Caused by MASH - GlobeNewsWire
- 3 months ago - Galectin Therapeutics Presents Three Abstracts at the American Association for the Study of Liver Diseases (AASLD) 2024 Liver Meeting - GlobeNewsWire
- 3 months ago - Galectin Therapeutics Reports Financial Results for the Quarter Ended September 30, 2024 and Provides Business Update - GlobeNewsWire
- 4 months ago - Galectin Therapeutics Announces Acceptance of Three Abstracts for the American Association for the Study of Liver Diseases (AASLD) 2024 Liver Meeting - GlobeNewsWire
- 6 months ago - Galectin Therapeutics to Present at the H.C. Wainwright 26th Annual Global Investment Conference - GlobeNewsWire
- 6 months ago - Galectin Therapeutics Reports Financial Results for the Quarter Ended June 30, 2024 and Provides Business Update - GlobeNewsWire